

Supplementary Table 1: Distribution of solicited and unsolicited adverse events by MedDRA High Level Group Term by treatment group and cycle (regular: 1-3, boost: 4). The figures in cells represent number of events followed by the number of participants in brackets.

	Vaccination 1 to 3 (blinded)					Vaccination 4 (optional - open)		
	SumayaVac-1			GLA-SE	0.9 % NaCl	SumayaVac-1		
	25 µg	50 µg	150 µg	5 µg	1 ml	25 µg	50 µg	150 µg
	<i>N</i> = 6	<i>N</i> = 12	<i>N</i> = 6	<i>N</i> = 4	<i>N</i> = 4	<i>N</i> = 5	<i>N</i> = 9	<i>N</i> = 4
Administration site reactions	28 (6)	101 (12)	29 (6)	16 (4)	14 (4)	8 (5)	17 (7)	8 (3)
Headaches	12 (5)	13 (7)	8 (4)	5 (3)	10 (2)	2 (1)	5 (3)	
General system disorders NEC	4 (2)	13 (8)	9 (4)	3 (1)	4 (3)		4 (2)	
Infections - pathogen unspecified	11 (6)	10 (7)	3 (3)	1 (1)	2 (2)	1 (1)	4 (3)	2 (2)
Epidermal and dermal conditions	1 (1)	14 (7)	2 (2)	3 (2)	2 (2)	1 (1)		1 (1)
Protein and chemistry analyses NEC	1 (1)	5 (3)	5 (3)	3 (2)		2 (2)	3 (2)	1 (1)
Gastrointestinal signs and symptoms	3 (3)	6 (4)	2 (1)	5 (1)			2 (2)	
Vascular haemorrhagic disorders	1 (1)	6 (4)	1 (1)	6 (3)				
Hepatobiliary investigations	2 (1)	5 (4)		2 (2)	1 (1)			1 (1)
Skin appendage conditions	3 (2)	3 (3)	2 (2)	1 (1)	1 (1)			
Haematology investigations (incl blood groups)	1 (1)	3 (3)	5 (2)					
Injuries NEC		3 (3)	3 (2)	1 (1)				2 (2)
Gastrointestinal motility and defaecation conditions		6 (4)	1 (1)		1 (1)			
Neurological disorders NEC	1 (1)	2 (1)	1 (1)	1 (1)	3 (1)			
Spleen, lymphatic and reticuloendothelial system disorders	1 (1)	5 (3)	1 (1)					1 (1)
Respiratory tract signs and symptoms	1 (1)	3 (2)		1 (1)		2 (1)		
Joint disorders	1 (1)				1 (1)	2 (1)	2 (2)	
Muscle disorders	2 (2)	1 (1)	2 (2)			1 (1)		
Musculoskeletal and connective tissue disorders NEC	2 (1)	2 (1)			1 (1)		1 (1)	
Body temperature conditions	2 (2)	2 (2)		1 (1)				

Table with 20 columns and 550 rows. Each row contains a long alphanumeric code followed by numerical values, some of which are enclosed in red boxes. The codes include various alphanumeric sequences such as '527 KDVDFARSARYTN', '528 DVDFARSARYTN', etc., up to '659 KNAQLQSHVYNY'. The numerical values range from 0 to over 4000, with some values in red boxes indicating specific data points.

Table with 10 columns and 550 rows, providing additional numerical data for each row. Values range from 0 to 1500. The 10th row contains a red box around the value 7.

Table with 45 columns and 1000 rows, containing numerical data and alphanumeric identifiers.


Table with 32 columns and 1000+ rows. Each row contains a 32-bit binary string and a corresponding numerical value. The binary strings are 32 bits long, with some rows having leading zeros. The numerical values are integers ranging from 0 to 1706. The table is organized into 1000 rows, each representing a different configuration or state.

Table with 33 columns and 500 rows. Each row contains a code (e.g., 1458 DLESHVKEEKEE) followed by 32 numerical values. The values are mostly integers, with some decimal points. The codes are alphanumeric strings of varying lengths. The numerical values range from 0 to over 5000. The table is organized into a grid-like structure with the codes in the first column and the numerical values in the subsequent columns.

528	Caucasian/White	31 1995	22	Female	25 ug MSP-1	7	7 common cold	No	Not related	Mild	Dose not changed	Recovered/ resolved	27/11/2017	Common cold	Nasopharyngitis	Infections and infestations	18	48	55
529	Caucasian/White	31 1995	22	Female	25 ug MSP-1	10	10 pain at injection site	No	(Definitely) related	Mild	Not applicable	Recovered/ resolved	01/12/2017	Injection site pain	Injection site pain	General disorders and administration site conditions	0	57	59
530	Caucasian/White	31 1995	22	Female	25 ug MSP-1	8	8 warmth at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	06/12/2017	Injection site warmth	Injection site warmth	General disorders and administration site conditions	1	58	64
531	Caucasian/White	31 1995	22	Female	25 ug MSP-1	9	9 induration at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	01/12/2017	Injection site induration	Injection site induration	General disorders and administration site conditions	1	58	59
532	Caucasian/White	31 1995	22	Female	25 ug MSP-1	11	11 Myalgia at upper arm, left	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	01/12/2017	Myalgia upper extremities	Myalgia	Musculoskeletal and connective tissue disorders	1	58	59
533	Caucasian/White	31 1995	22	Female	25 ug MSP-1	12	12 Headache	No	Unlikely	Mild	Not applicable	Recovered/ resolved	13/12/2017	Headache	Headache	Nervous system disorders	14	71	71
534	Caucasian/White	31 1995	22	Female	25 ug MSP-1	13	13 Headache	No	Unlikely	Moderate	Not applicable	Recovered/ resolved	20/12/2017	Headache	Headache	Nervous system disorders	20	77	78
535	Caucasian/White	31 1995	22	Female	25 ug MSP-1	14	14 Pain at injection site	No	(Definitely) related	Moderate	Not applicable	Recovered/ resolved	23/03/2018	Injection site pain	Injection site pain	General disorders and administration site conditions	1	170	171
536	Caucasian/White	31 1995	22	Female	25 ug MSP-1	15	15 CRP increased	No	(Definitely) related	Moderate	Not applicable	Recovered/ resolved	28/03/2018	C-reactive protein increased	C-reactive protein increased	Investigations	2	171	176
537	Caucasian/White	31 1995	22	Female	25 ug MSP-1	16	16 Lymphopenia	No	Possible	Mild	Not applicable	Recovered/ resolved	28/03/2018	Lymphopenia	Lymphopenia	Blood and lymphatic system disorders	2	171	176
538	Caucasian/White	31 1995	22	Female	25 ug MSP-1	17	17 Ear pain, left	No	Unlikely	Mild	Not applicable	Recovered/ resolved	27/03/2018	Ear pain	Ear pain	Ear and labyrinth disorders	5	174	175
539	Caucasian/White	31 1995	22	Female	25 ug MSP-1	18	18 Headache	No	Possible	Mild	Not applicable	Recovered/ resolved	27/03/2018	Headache	Headache	Nervous system disorders	5	174	175
540	Caucasian/White	31 1995	22	Female	25 ug MSP-1	19	19 Gastroenteritis	No	Unlikely	Mild	Not applicable	Recovered/ resolved	07/04/2018	Gastroenteritis	Gastroenteritis	Infections and infestations	13	182	186
541	Caucasian/White	31 1995	22	Female	25 ug MSP-1	20	20 Lymphopenia	No	Possible	Mild	Not applicable	Recovered/ resolved	18/04/2018	Lymphopenia	Lymphopenia	Blood and lymphatic system disorders	14	183	197
542	Caucasian/White	31 1995	22	Female	25 ug MSP-1	21	21 Headache	No	Possible	Mild	Not applicable	Recovered/ resolved	17/04/2018	Headache	Headache	Nervous system disorders	27	196	196
543	Caucasian/White	32 1996	21	Female	150 ug MSP-1	1	1 pain at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	07/10/2017	Injection site pain	Injection site pain	General disorders and administration site conditions	0	1	4
544	Caucasian/White	32 1996	21	Female	150 ug MSP-1	3	3 fatigue	No	Probable	Mild	Dose not changed	Recovered/ resolved	05/10/2017	Fatigue	Fatigue	General disorders and administration site conditions	0	1	2
545	Caucasian/White	32 1996	21	Female	150 ug MSP-1	5	5 cephalgie	No	Probable	Mild	Dose not changed	Recovered/ resolved	05/10/2017	Cephalgia	Headache	Nervous system disorders	0	1	2
546	Caucasian/White	32 1996	21	Female	150 ug MSP-1	6	6 sweating	No	Probable	Mild	Dose not changed	Recovered/ resolved	05/10/2017	Sweating	Hyperhidrosis	Skin and subcutaneous tissue disorders	0	1	2
547	Caucasian/White	32 1996	21	Female	150 ug MSP-1	2	2 warmth at injection site	No	Probable	Mild	Dose not changed	Recovered/ resolved	07/10/2017	Injection site warmth	Injection site warmth	General disorders and administration site conditions	2	3	4
548	Caucasian/White	32 1996	21	Female	150 ug MSP-1	4	4 hematoma at injection site	No	Probable	Mild	Dose not changed	Recovered/ resolved	13/10/2017	Hematoma injection site	Injection site haematoma	General disorders and administration site conditions	5	6	10
549	Caucasian/White	32 1996	21	Female	150 ug MSP-1	7	7 pain at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	08/11/2017	Injection site pain	Injection site pain	General disorders and administration site conditions	1	31	36
550	Caucasian/White	32 1996	21	Female	150 ug MSP-1	8	8 swelling at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	04/11/2017	Injection site swelling	Injection site swelling	General disorders and administration site conditions	1	31	32
551	Caucasian/White	32 1996	21	Female	150 ug MSP-1	9	9 pruritus at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	04/11/2017	Injection site pruritus	Injection site pruritus	General disorders and administration site conditions	1	31	32
552	Caucasian/White	32 1996	21	Female	150 ug MSP-1	10	10 warmth at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	08/11/2017	Injection site warmth	Injection site warmth	General disorders and administration site conditions	1	31	36
553	Caucasian/White	32 1996	21	Female	150 ug MSP-1	11	11 Erythema at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	08/11/2017	Injection site erythema	Injection site erythema	General disorders and administration site conditions	2	32	36
554	Caucasian/White	32 1996	21	Female	150 ug MSP-1	12	12 Rash (sural, both sides)	No	Possible	Mild	Dose not changed	Recovered/ resolved	06/11/2017	Rash both legs	Rash	Skin and subcutaneous tissue disorders	2	32	34
555	Caucasian/White	32 1996	21	Female	150 ug MSP-1	13	13 warmth at injection site	No	(Definitely) related	Mild	Dose not changed	Recovered/ resolved	29/11/2017	Injection site warmth	Injection site warmth	General disorders and administration site conditions	0	57	57
556	Caucasian/White	32 1996	21	Female	150 ug MSP-1	14	14 Abdominal pain	No	Unlikely	Mild	Dose not changed	Recovered/ resolved	07/12/2017	Abdominal pain	Abdominal pain	Gastrointestinal disorders	7	64	65
557	Caucasian/White	32 1996	21	Female	150 ug MSP-1	15	15 Nausea	No	Unlikely	Mild	Dose not changed	Recovered/ resolved	07/12/2017	Nausea	Nausea	Gastrointestinal disorders	7	64	65
558	Caucasian/White	32 1996	21	Female	150 ug MSP-1	16	16 Diarrhea	No	Unlikely	Mild	Dose not changed	Recovered/ resolved	07/12/2017	Diarrhea	Diarrhoea	Gastrointestinal disorders	7	64	65
559	Caucasian/White	32 1996	21	Female	150 ug MSP-1	17	17 Hematoma at place of i.v. catheter left	No	Not related	Mild	Not applicable	Recovered/ resolved	18/04/2018	Catheter site haematoma	Catheter site haematoma	General disorders and administration site conditions	1	191	197
560	Caucasian/White	32 1996	21	Female	150 ug MSP-1	19	19 CRP increased	No	Possible	Mild	Not applicable	Recovered/ resolved	25/04/2018	CRP increased	C-reactive protein increased	Investigations	2	192	204
561	Caucasian/White	32 1996	21	Female	150 ug MSP-1	18	18 Inversion ankle sprain left	No	Not related	Mild	Not applicable	Recovered/ resolved	30/11/2018	Ankle sprain	Ligament sprain	Injury, poisoning and procedural complications	4	194	423
562	Caucasian/White	32 1996	21	Female	150 ug MSP-1	20	20 Common cold symptoms	No	Possible	Mild	Not applicable	Recovered/ resolved	13/05/2018	Common cold	Nasopharyngitis	Infections and infestations	25	215	222

Variables in Creation Order

#	Variable	Type	Label
1	ethnic	Char	
2	STUDYID	Char	Study ID
3	SITEID	Char	Currently treating site
4	USUBJID	Num	Participant ID
5	BIRTHDTC	Char	Year of birth
6	AGE	Num	Age at day of inclusion
7	SEX	Num	Gender
8	armcd	Num	Treatment group
16	AESEQ	Num	AE No. (unified per patient)
17	AESPID	Num	AE CRF No
18	AETERM	Char	Description of AE (only one finding per row)
19	AESER	Num	Serious?
20	AEREL	Num	Relatedness
22	AESEV	Num	CTCAE-grade
23	AEINTER	Num	Intermittent
24	AEACN	Num	Action taken
25	AEOUT	Num	Outcome
30	Split_No_	Num	Split No#
31	LLT	Num	LLT
32	PT	Num	PT
33	SOC	Num	SOC
34	LLT_Coded_Term	Char	LLT_Coded_Term
35	PT_Coded_Term	Char	PT_Coded_Term
36	SOC_Coded_Term	Char	SOC_Coded_Term
49	aedosdur	Num	
50	aestdy	Num	Study Day of start of AE
51	aeendy	Num	Study Day of end of AE



Supplementary Fig. 1 PBMCs from six volunteers immunized three times with SumayaVac-1 were stimulated with a monoclonal antibody against CD3 in the cultured ELISpot assay.